Craig Lindsley
-
Committed to Memory: VU319 may hold the key to improving memory loss in Alzheimer’s patients
VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease. Read MoreJul 23, 2020
-
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read MoreJun 16, 2020
-
Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science
Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science." Read MoreJun 12, 2020
-
Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders
Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs. Read MoreMay 5, 2020
-
Lindsley named fellow of National Academy of Inventors
Craig Lindsley, co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been named a fellow of the National Academy of Inventors. Read MoreJan 4, 2019
-
What’s On My Mind: The bright points of 2018
Chancellor Nicholas S. Zeppos reflects on Vanderbilt's work, progress and accomplishments over the past 12 months in his final column of 2018. Read MoreDec 21, 2018
-
Lindsley named to National Academy of Inventors
Craig W. Lindsley, William K. Warren Jr. Professor of Medicine and co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been elected a fellow of the prestigious National Academy of Inventors. Read MoreDec 11, 2018
-
Ancora announces major funding awards to support Vanderbilt drug discovery research
Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding. Read MoreNov 26, 2018
-
AAAS, chemistry society honor Lindsley’s research contributions
Craig Lindsley, PhD, co-director of the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD), has been named a fellow of the Royal Society of Chemistry and elected chair-elect of the Section of Pharmaceutical Sciences of the American Association for the Advancement of Science (AAAS). Read MoreFeb 1, 2018
-
Vanderbilt researchers’ papers among those most cited
Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers. Read MoreDec 7, 2017
-
Lindsley honored by Pharmaceutical Society of Japan
Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan. Read MoreDec 7, 2017
-
University of Kansas honors Lindsley’s pharmacology research
Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology. Read MoreSep 21, 2017
-
Vanderbilt begins Phase 1 trials of new Alzheimer’s drug
Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read MoreAug 7, 2017
-
Vanderbilt, Ono Pharmaceutical extend drug discovery agreement
Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019. Read MoreMay 25, 2017
-
Lindsley’s drug discovery efforts land ASPET Award
Craig Lindsley, Ph.D., a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is the 2017 recipient of the Pharmacia-ASPET Award in Experimental Therapeutics from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Read MoreJan 12, 2017
-
Investigational new drug for Alzheimer’s scheduled for first study in humans
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read MoreDec 27, 2016
-
Nine Vanderbilt faculty members elected AAAS fellows
Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year. Read MoreNov 25, 2016
-
Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt
Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation. Read MoreAug 15, 2016
-
Vanderbilt, Ono Pharmaceutical sign drug discovery agreement
Vanderbilt University Medical Center and Ono Pharmaceutical Group, an international company based in Japan, have signed a drug discovery agreement. Read MoreDec 10, 2015
-
Five VUMC faculty members on list of most frequently cited researchers
Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others. Read MoreOct 8, 2015